Wednesday, October 14, 2026

How We Source Explore Search

Via News Knowledge File

Yahoo Finance

organization80% conf.·synced Aug 13, 2026

Financial news and media company producing Morning Brief program

0

sourced metrics

936

relationships

0

stated objectives

8

Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Relationship graph · 936 connections

Employs

746

Covered by

65

merged with

23

employed by

23

subsidiary of

20

Owns

12

allied with

10

Partners with

5

Via News coverage

Chip Sector Splits: Record Amkor Earnings, $5B Nvidia-Backed SSI Deal Diverge From Stock Selloff

August 11, 2026

Central Bank Gold Tops $4 Trillion, Overtaking US Treasuries for First Time

88% of Enterprise Leaders Regret Rushing Agentic AI Without Governance Foundations

30-Year Treasury Yields Break 5% as Fed Transition Widens Fiscal Risk Premium

Powell's Exit Leaves Fed Rudderless as CPI Holds at 3.8% and Yields Breach 5%

Nvidia's 20% Surge and a 2027 Rare Earth Ban Are Reshaping the Semiconductor Investment Stack

Warsh Inherits Fed With U.S. CPI at 3.8% and Markets Pricing Out 2026 Rate Cuts

Gasoline Tops $4 as Hormuz Closure Drives 1970s-Style Stagflation Threat

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe

October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,375 source documents archived

Query this data → isubstrate.com